Dr. Heidi Overton faces questions on mifepristone, vaccines at Senate confirmation hearing

What This is

• Dr. Heidi Overton appeared before the Senate Health, Education, Labor, and Pensions Committee as Trump’s pick to run the FDA.
• Senators questioned her about mifepristone, including her past criticism of allowing the drug to be prescribed by telemedicine and shipped by mail.
• Overton said mifepristone has met FDA safety and effectiveness standards and pointed to continued safety monitoring after approval.
• Overton said the MMR shot and other recommended vaccines are safe and effective, but she avoided directly saying Trump was wrong about his “quite lethal” claim.
• Vaccine policy was a major focus, including questions about changes to the childhood vaccine schedule and her past support for splitting vaccine timing.
• Lawmakers and others also raised concerns about her management experience as the FDA deals with staff departures and ongoing public trust concerns.

Why This Matters

• The FDA commissioner can shape which drugs and vaccines stay available, how they are used, and how hard the agency pushes on safety risks.
• Rules for telemedicine and mailing mifepristone can change access in practice, even without changing abortion laws.
• If leaders send mixed messages about vaccine safety, more people may skip shots, increasing the risk of outbreaks of measles and other preventable diseases.
• Perceived political pressure on FDA decisions can weaken trust in the agency and reduce public and industry compliance with health guidance.